Patent ID: 9316644
Filing Date: 2016-04-19
CPC Classification: A61P,G01N

Claim Text:
1. A method for treating a human tumor in a patient, comprising determining the sensitivity of said human tumor to a combination of capecitabine, a COX-2 inhibitor, and an angiogenesis inhibitor, comprised of the following steps: (a) obtaining a tumor tissue sample from said human tumor; (b) testing said tumor tissue sample to determine a first amount of a group of indicators including thymidine phosphorylase, vascular endothelial growth factor (VEGF), vascular endothelial growth factor-receptor (VEGF-R), and cyclooxygenase 2, wherein the thymidine phosphorylase is detected from a peritumoral fraction of said tumor tissue sample; (c) comparing the first amount of each of said group of indicators to a second amount of said group of indicators, wherein said second amount of said group of indicators is obtained from a non-tumor tissue sample; and (d) determining the sensitivity of said human tumor to capecitabine in combination with the COX-2 inhibitor and the angiogenesis inhibitor, wherein when the first amount is greater than the second amount, the test is indicative of sensitivity, and wherein when the first amount is less than the second amount, the test is indicative of insensitivity; and, (e) when the test is indicative of sensitivity, administering to said patient harboring the human tumor capecitabine in combination with the COX-2 inhibitor and the angiogenesis inhibitor.